Enzyme Finance-logo

Enzyme Finance

Enzyme Finance, formerly known as Melon Protocol, is an Ethereum-based protocol for decentralized on-chain asset management. It is a protocol for people or entities to manage their wealth & the wealth of others within a customizable and safe environment. Enzyme empowers anyone to set up, manage and invest in customized on-chain investment vehicles.

ETH
Polygon
Defi
Asset Management
Solidity
Maximum Bounty
$400,000
Live Since
29 March 2021
Last Updated
20 November 2024
  • PoC required

Rewards

Enzyme Finance provides rewards in USDC on Ethereum, denominated in USD.

Rewards by Threat Level

Smart Contract
Critical
Flat: $400,000
Primacy of Rules
High
Flat: $80,000
Primacy of Rules
Medium
Flat: $20,000
Primacy of Rules
Low
Flat: $2,000
Primacy of Rules
Critical Reward Calculation

Mainnet assets:

Reward amount is 10% of the funds directly affected up to a maximum of:

$400,000

Rewards are distributed according to the impact of the vulnerability based on the Immunefi Vulnerability Severity Classification System. This is a simplified 5-level scale encompassing everything from consequence of exploitation to privilege required to likelihood of a successful exploit.

The final reward amount for critical smart contract vulnerabilities is capped at 10% of the funds at risk based on the vulnerability reported.

All bug reports must come with a PoC. If a bug report does not have a PoC it will be rejected with instructions to provide a PoC

All payouts are done by the Enzyme Finance team directly and are denominated in USD. Payouts are done in USDC up to USD $400,000.

Program Overview

Enzyme Finance, formerly known as Melon Protocol, is an Ethereum-based protocol for decentralized on-chain asset management. It is a protocol for people or entities to manage their wealth & the wealth of others within a customizable and safe environment. Enzyme empowers anyone to set up, manage and invest in customized on-chain investment vehicles.

More information about Enzyme Finance can be found in their docs and also here in the additional V4 docs. See especially the Known Risks & Mitigations.

This bug bounty program is focused around the Enzyme Finance smart contracts and is primarily concerned with the loss of user funds.

KYC not required

No KYC information is required for payout processing.

Proof of Concept

Proof of concept is always required for all severities.

Prohibited Activities

Default prohibited activities
  • Any testing on mainnet or public testnet deployed code; all testing should be done on local-forks of either public testnet or mainnet
  • Any testing with pricing oracles or third-party smart contracts
  • Attempting phishing or other social engineering attacks against our employees and/or customers
  • Any testing with third-party systems and applications (e.g. browser extensions) as well as websites (e.g. SSO providers, advertising networks)
  • Any denial of service attacks that are executed against project assets
  • Automated testing of services that generates significant amounts of traffic
  • Public disclosure of an unpatched vulnerability in an embargoed bounty
  • Any other actions prohibited by the Immunefi Rules

Feasibility Limitations

The project may be receiving reports that are valid (the bug and attack vector are real) and cite assets and impacts that are in scope, but there may be obstacles or barriers to executing the attack in the real world. In other words, there is a question about how feasible the attack really is. Conversely, there may also be mitigation measures that projects can take to prevent the impact of the bug, which are not feasible or would require unconventional action and hence, should not be used as reasons for downgrading a bug's severity.

Therefore, Immunefi has developed a set of feasibility limitation standards which by default states what security researchers, as well as projects, can or cannot cite when reviewing a bug report.

Severity
Min. - Max.
Critical
$400k
High
$80k
Medium
$20k
Low
$2k
Total paid

622.5k

Med. Resolution Time
1 hour
Total Assets in Scope
265